One- and 2-year rates of PFS, OS, and patients remaining treatment-free (intent-to-treat population)
| Outcome . | % (95% CI) . | Hazard ratio* (95% CI) . | P† . | |
|---|---|---|---|---|
| VR-CAP, n = 84 . | R-CHOP, n = 80 . | |||
| PFS rate‡ | ||||
| 1-y | 80.0 (69.0-87.5) | 82.3 (71.4-89.3) | 1.12 (0.57-2.20) | .76 |
| 2-y | 76.2 (64.2-84.7) | 77.1 (65.1-85.4) | ||
| OS rate | ||||
| 1-y | 91.2 (82.3-95.7) | 85.9 (76.0-92.0) | 0.89 (0.44-1.81) | .75 |
| 2-y | 80.1 (69.0-87.5) | 79.0 (67.9-86.6) | ||
| Treatment-free rate§ | ||||
| 1-y | 70.6 (59.2-79.4) | 78.4 (67.2-86.2) | 1.25 (0.69-2.24) | .49 |
| 2-y | 69.3 (57.8-78.3) | 71.8 (59.6-80.9) | ||
| Outcome . | % (95% CI) . | Hazard ratio* (95% CI) . | P† . | |
|---|---|---|---|---|
| VR-CAP, n = 84 . | R-CHOP, n = 80 . | |||
| PFS rate‡ | ||||
| 1-y | 80.0 (69.0-87.5) | 82.3 (71.4-89.3) | 1.12 (0.57-2.20) | .76 |
| 2-y | 76.2 (64.2-84.7) | 77.1 (65.1-85.4) | ||
| OS rate | ||||
| 1-y | 91.2 (82.3-95.7) | 85.9 (76.0-92.0) | 0.89 (0.44-1.81) | .75 |
| 2-y | 80.1 (69.0-87.5) | 79.0 (67.9-86.6) | ||
| Treatment-free rate§ | ||||
| 1-y | 70.6 (59.2-79.4) | 78.4 (67.2-86.2) | 1.25 (0.69-2.24) | .49 |
| 2-y | 69.3 (57.8-78.3) | 71.8 (59.6-80.9) | ||
R-CHOP vs VR-CAP; a HR of <1 indicates an advantage for VR-CAP.
Based on the log-rank test (stratified by International Prognostic Index score).
PFS rate by Independent Radiology Review Committee assessment.
Patients who had not received subsequent lymphoma therapy or had not died due to progressive disease.